Why Early Phase Modeling Is Key To Reimbursement And Patient Access

Gaining market access poses a significant challenge for companies, often necessitating a unique approach to gather evidence for reimbursement negotiations. Early phase modeling emerges as a valuable tool, aiding in assessing the feasibility of future adoption, shaping product development strategies, facilitating investor communication, and even influencing decisions regarding product development pursuits. This podcast delves into the realm of early phase modeling, elucidating its significance and evolution as a critical element in securing reimbursement and enhancing patient access.

Speaker Bio: Annabelle Fosmark is Senior Manager, Health Economics & Outcomes Research at PharmaLex and has vast experience in managing projects concerning all the Nordic markets, including reimbursement dossiers, supporting payer negotiation processes, health economic modelling, evaluation of clinical and health economic data, and strategic advice on market access.